Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
NCT04669158
Digestive System Diseases, Fatty Liver
Redwood City, California, United States
View Trial DetailsNCT Number: NCT03432377
The aim of our study is to evaluate the effect of coffee consumption on the risk of severe liver fibrosis in French patients with NASH.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Centre Hospitalier de Béziers, Béziers, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Any newly diagnosed case of NASH histologically proven graded according to SAF criteria
Or Metabolic syndrome defined by the IDF 2005 criteria:
Exclusion criteria
Time frame: Day 0
Time frame: Day 0
Time frame: Day 0
Time frame: Day 0
Versailles Hospital
Other
Acronym: COCANASH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04669158
Digestive System Diseases, Fatty Liver
Redwood City, California, United States
View Trial DetailsNCT05357352
Digestive System Diseases, Fatty Liver
Dallas, Texas, United States
View Trial DetailsNCT03863574
Digestive System Diseases, Fatty Liver
Jackson, Mississippi, United States
View Trial DetailsNCT04573543
Biomarkers, Digestive System Diseases
Zagreb, Croatia
View Trial Details